RECRUITING

Vasoactive Drugs in Intensive Care Unit

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The investigators hypothesis is that for ICU patients with shock, the use of the vasoactive drugs phenylephrine and vasopressin will reduce tachydysrhythmias when compared to norepinephrine and epinephrine. To investigate this hypothesis, the investigators are conducting a randomized double blind controlled trial comparing phenylephrine and vasopressin vs. norepinephrine and epinephrine in ICU patients with shock that is not responsive to IV fluids. All patients admitted to the adult intensive care units at the University of Chicago will be screened for eligibility.

Official Title

A Randomized Double Blind Trial of Vasoactive Drugs for the Management of Shock in the ICU

Quick Facts

Study Start:2014-05
Study Completion:2025-12
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT02118467

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:ALL
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. 1. Age greater than or equal to 18 years old
  2. 2. Requirement for vasoactive drugs via a central venous catheter for the treatment of shock. Shock will be defined as mean arterial pressure less than 70 mmHg or systolic blood pressure less than 100 mmHg despite administration of at least 1000 mL of crystalloid or 500 mL of colloid, unless there is an elevation in the central venous pressure to \> 12 mmHg or in the pulmonary artery occlusion pressure to \> 14 mmHg coupled with signs of tissue hypoperfusion (e.g. altered mental state, mottled skin, urine output \< 0.5 mL/kg body weight for one hour, or a serum lactate level of \> 2 mmol per liter).
  1. 1. Cardiopulmonary arrest
  2. 2. Pregnancy
  3. 3. Severe right heart failure

Contacts and Locations

Study Contact

John P Kress, MD
CONTACT
773-702-6404
jkress@medicine.bsd.uchicago.edu
Anne Pohlman
CONTACT
6302487461
apohlman@medicine.bsd.uchicago.edu

Principal Investigator

John P Kress, MD
PRINCIPAL_INVESTIGATOR
University of Chicago

Study Locations (Sites)

University of Chicago Medical Center
Chicago, Illinois, 60637
United States

Collaborators and Investigators

Sponsor: University of Chicago

  • John P Kress, MD, PRINCIPAL_INVESTIGATOR, University of Chicago

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2014-05
Study Completion Date2025-12

Study Record Updates

Study Start Date2014-05
Study Completion Date2025-12

Terms related to this study

Keywords Provided by Researchers

  • Shock
  • Vasopressor agents
  • Norepinephrine
  • Epinephrine
  • Phenylephrine
  • Vasopressin
  • Atrial fibrillation
  • Tachyarrhythmia

Additional Relevant MeSH Terms

  • Shock